Regenicin (Regenicin) Treasury Stock : $-0.00 Mil (As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Regenicin's treasury stock for the quarter that ended in Mar. 2023 was $-0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Regenicin Treasury Stock Historical Data

The historical data trend for Regenicin's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Treasury Stock Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Treasury Stock

Get a 7-Day Free Trial

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Regenicin Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines